Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial

Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial

BackgroundChronic kidney disease-associated pruritus (CKD-aP) is a common and distressing symptom in hemodialysis patients. This Phase II trial evaluated the efficacy and safety of HSK21542, a selective kappa-opioid receptor agonist, in managing CKD-aP.MethodsAdult patients on hemodialysis with mode...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming-Ming Pan, Min Gao, Li Zhou, Yan Xu, Li Yao, Chao-Qing Wu, Chang-Lin Mei, Zhan-Zheng Zhao, Dong Sun, Tian-Jun Guan, Qin-Kai Chen, Ming Shi, Hui Xu, Ya-Ming Li, Wan-Yun Zhao, Rui Yan, Bi-Cheng Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
CKD-aP
HSK21542
hemodialysis
κ-opioid receptor agonist
uremic pruritus
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1583515/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1583515/full

Similar Items